New NK cell treatments for lymphoma patients who didn't respond to CAR-T therapy.
Official title: Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.
Funded at University of Tx Md Anderson Can Ctr · NIH-11041192 · Data updated 2026-11-12
This study is looking at new ways to use natural killer (NK) cells to help patients with certain blood cancers who haven't had success with previous CAR-T cell treatments, aiming to create a safer and more effective option for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $333,518 |
| NIH project number | 5R01CA280827-03 |
| Project ID | NIH-11041192 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are lymphoma patients who have experienced a relapse after CD19 CAR-T cell therapy.
✕Less likely to help
Patients who have not undergone CAR-T therapy or those with other types of malignancies may not benefit from this research.
What this research studies
This research focuses on developing next-generation natural killer (NK) cell therapies for patients with B-cell lymphoid malignancies who have relapsed after receiving CD19 CAR-T cell therapy. The approach involves enhancing the effectiveness and longevity of NK cells through advanced techniques such as costimulatory signaling and checkpoint inhibition. By targeting specific tumor antigens, this research aims to provide a safer and more effective treatment option for patients who have limited choices after CAR-T therapy failure.
Why it matters
Potential benefit: If successful, this research could offer a new, effective treatment option for lymphoma patients who have not responded to existing therapies.
How similar studies have gone: Previous studies have shown promising results with similar NK cell therapies, indicating potential for success in this novel approach.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Daher, May — University of Tx Md Anderson Can Ctr
- Study coordinator: Daher, May
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Radiation Therapy Innovation to Improve Lymphoma Trials and Carbon Ion Research Path
A Mayo Clinic-led effort to better design and run lymphoma trials by integrating advanced radiation therapy and exploring carbon ion radiotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.